Recent returns and business profile Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after a period where its share price total return is 0.3% over the past 3 months and 15.4% year to date, ...

Takeda Pharmaceutical struck one of the biggest life science deals of 2022, acquiring a clinical-stage Nimbus Therapeutics drug addressing a promising new target for autoimmune disorders. Other than ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the most promising stocks under $20. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the New Drug ...

Takeda Pharmaceutical Company Limited ( TAK) TD Cowen 46th Annual Health Care Conference March 2, 2026 1:10 PM EST ...

Takeda Pharmaceutical said Tuesday it has committed up to a staggering $6 billion—including $4 billion upfront—to acquire from Nimbus Therapeutics a candidate for multiple autoimmune diseases that is ...

Cell therapies made from a patient’s own immune cells found their first successes treating blood cancers. Getting T cells to treat solid tumors has been a tougher task. Maverick Therapeutics has just ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug reduced blood procedures among patients with a rare type of cancer in a phase 3 ...

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and ...

Takeda has already faced claims it used an illegal "pay-for-delay" deal to push back competition to constipation drug Amitiza. Now, a group of drug purchasers is going after the company, alleging ...

Takeda is making its first foray into rare disease marketing on connected TV (CTV). The Japanese biotech recently launched a video campaign for its chronic inflammatory demyelinating polyneuropathy ...

Takeda Pharmaceutical Co.’s 2019 acquisition of its larger European rival Shire PLC made it one of the most indebted drugmakers in the world. Four years later, Takeda has not only brought its debt ...